Brigatinib: First Global Approval

被引：125

作者：

Markham, Anthony ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2017年 / 77卷 / 10期

关键词：

D O I：

10.1007/s40265-017-0776-3

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Brigatinib (ALUNBRIG (TM)) is a small molecule antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company). In April 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants. This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.

引用

页码：1131 / 1135

页数：5

共 4 条

[1]

ARIAD Pharmaceuticals Inc, 2017, ALUNBRIG BRIG US PRE

[2]

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial [J].

Gettinger, Scott N. ;

Bazhenova, Lyudmila A. ;

Langer, Corey J. ;

Salgia, Ravi ;

Gold, Kathryn A. ;

Rosell, Rafael ;

Shaw, Alice T. ;

Weiss, Glen J. ;

Tugnait, Meera ;

Narasimhan, Narayana I. ;

Dorer, David J. ;

Kerstein, David ;

Rivera, Victor M. ;

Clackson, Timothy ;

Haluska, Frank G. ;

Camidge, David Ross .

LANCET ONCOLOGY, 2016, 17 (12) :1683-1696

[3]

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial [J].

Kim, Dong-Wan ;

Tiseo, Marcello ;

Ahn, Myung-Ju ;

Reckamp, Karen L. ;

Hansen, Karin Holmskov ;

Kim, Sang-We ;

Huber, Rudolf M. ;

West, Howard L. ;

Groen, Harry J. M. ;

Hochmair, Maximilian J. ;

Leighl, Natasha B. ;

Gettinger, Scott N. ;

Langer, Corey J. ;

Rodriguez, Luis G. Paz-Ares ;

Smit, Egbert F. ;

Kim, Edward S. ;

Reichmann, William ;

Haluska, Frank G. ;

Kerstein, David ;

Camidge, D. Ross .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (22) :2490-+

[4]

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models [J].

Zhang, Sen ;

Anjum, Rana ;

Squillace, Rachel ;

Nadworny, Sara ;

Zhou, Tianjun ;

Keats, Jeff ;

Ning, Yaoyu ;

Wardwell, Scott D. ;

Miller, David ;

Song, Youngchul ;

Eichinger, Lindsey ;

Moran, Lauren ;

Huang, Wei-Sheng ;

Liu, Shuangying ;

Zou, Dong ;

Wang, Yihan ;

Mohemmad, Qurish ;

Jang, Hyun Gyung ;

Ye, Emily ;

Narasimhan, Narayana ;

Wang, Frank ;

Miret, Juan ;

Zhu, Xiaotian ;

Clackson, Tim ;

Dalgarno, David ;

Shakespeare, William C. ;

Rivera, Victor M. .

CLINICAL CANCER RESEARCH, 2016, 22 (22) :5527-5538

← 1 →